Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Dr Bellmunt on the Design of the IMvigor011 Trial of ctDNA-Guided Adjuvant Atezolizumab in MIBC

November 12th 2025

Joaquim Bellmunt, MD, PhD, discusses the phase 3 IMvigor011 trial of ctDNA-guided adjuvant atezolizumab in MIBC.

Dr George on the Role of Radioligand Therapy in Prostate Cancer Management

November 12th 2025

Daniel J. George, MD, discusses the potential of radioligand therapies for patients with prostate cancer and the evolution of this treatment paradigm.

Ifinatamab Deruxtecan Development Continues in Phase 3 Study After Robust Results in Pretreated ES-SCLC

November 12th 2025

Based on its previously demonstrated activity and tolerability in ES-SCLC, I-DXd will be examined in the phase 3 IDeate-Lung02 trial.

Anito-Cel Emerges as Potential Novel Option in R/R Multiple Myeloma

November 12th 2025

Anito-cel produced high ORR and sCR/CR rates in patients with relapsed/refractory multiple myeloma.

Oncology Experts and AI Advocates Explain the Evolving Role of AI in Insurance Appeals

November 12th 2025

Using AI to automate oncology insurance prior authorization submissions could help lighten the load for health care professionals and speed access to care.

NALIRIFOX Expands Frontline Options in Metastatic Pancreatic Cancer

November 11th 2025

Dong Kim, MD, discusses the role of NALIRIFOX and other frontline chemotherapy regimens in the pancreatic cancer treatment landscape.

Early Activity With DB-1305/BNT325 Signals Potential Expansion of TROP-2 ADCs in Pretreated Metastatic TNBC

November 10th 2025

Erika P. Hamilton, MD, discusses initial efficacy and safety data with the TROP2-targeted ADC DB-1305/BNT325 in pretreated metastatic TNBC.

Lutetium Lu 177 Vipivotide Tetraxetan Enables Some Patients with mCRPC to Avoid Chemotherapy

November 10th 2025

Daniel J. George, MD, discusses the role of lutetium Lu 177 vipivotide tetraxetan in metastatic CRPC and patient selection considerations.

Pharmacists Play Key Role in Patient Education and Treatment Adherence in CML Management

November 10th 2025

Jose Tinajero, PharmD, BCOP, discusses the role of the pharmacist in treatment planning and management in chronic myeloid leukemia.

NCCN Releases NSCLC Guideline Update, Dato-DXd Designated as a Preferred Second-Line Regimen in EGFR-Mutated Disease

November 10th 2025

The NCCN has released their updated Clinical Practice Guidelines in Oncology for NSCLC.

Bezuclastinib Plus Sunitinib Shows PFS Benefit in Second-Line GIST

November 10th 2025

The phase 3 PEAK trial met its primary PFS end point with bezuclastinib plus sunitinib in imatinib-resistant/intolerant gastrointestinal stromal tumors.

Zanzalintinib Plus Atezolizumab Signals New Progress for Previously Treated mCRC

November 10th 2025

Anwar Saeed, MD, discusses findings of zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer.

Dr Wang on the Safety Profile of CNS Bridging Radiotherapy Prior to CAR T in B-Cell Lymphoma

November 6th 2025

Pule Wang, MD, discusses safety data with CNS bridging radiotherapy before CAR T in B-cell lymphoma.

Dr Tagawa on the Efficacy of Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC

November 6th 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the efficacy of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.

Dr Jakubowiak on the ATLAS Trial of Carfilzomib, Lenalidomide, and Dexamethasone in Myeloma

November 6th 2025

Andrzej Jakubowiak, MD, PhD, discusses the rationale of the phase 3 ATLAS study in patients with multiple myeloma.

Dr Yuan on the Potential Benefit of Upfront T-DXd in HER2+ Breast Cancer With CNS Metastases

November 6th 2025

Yuan Yuan, MD, PhD, discusses questions regarding the potential benefit of T-DXd in first line regimens for HER2-positive breast cancer with CNS metastases.

Adjuvant Durvalumab Plus Tremelimumab Yields DFS Advantage in Resected RCC

November 6th 2025

Treatment with adjuvant durvalumab plus tremelimumab resulted in a DFS benefit vs active monitoring in RCC, particularly in the higher-risk population.

UGN-103 Yields High 3-Month CR Rate in Low-Grade, Intermediate-Risk NMIBC

November 6th 2025

UGN-103 produced a 77.8% 3-month CR rate in patients with low-grade, intermediate-risk NMIBC.

ChatGPT Fails to Provide Up-to-Date and Specific Information for Specific Queries in Hematologic Malignancies

November 6th 2025

Justin Taylor, MD, discusses findings from a study that evaluated the ability of ChatGPT to offer specific information in hematologic malignancies.

Dr Visco on Unmet Needs for Patients With Mantle Cell Lymphoma

November 6th 2025

Carlo Visco, MD, explains the need to study treatment outcomes and develop novel therapies for patients with mantle cell lymphoma harboring TP53 mutations.